Primary source: HSA
HSA Singapore issued a Field Safety Notice for all HeartWare Ventricular Assist System batteries due to potential performance issues.
Battery performance issues in the HeartWare Ventricular Assist System could lead to device malfunction, posing serious risks to patients reliant on the system for cardiac support.
Identify and quarantine affected HeartWare batteries; follow manufacturer's instructions for battery management and replacement; ensure patients and healthcare providers are informed.
Regulatory Intelligence Lead
As needed per manufacturer updates or further HSA communications.
Healthcare providers and patients should follow the specific battery management and replacement instructions provided by the manufacturer.
Identify and quarantine affected HeartWare batteries; follow manufacturer's instructions for battery management and replacement; ensure patients and healthcare providers are informed.
The Health Sciences Authority (HSA) of Singapore published a Field Safety Notice for HeartWare Ventricular Assist System batteries due to potential performance issues. Healthcare providers and patients are instructed to follow specific battery management and replacement instructions from the manufacturer.
What changed: HSA Singapore issued a Field Safety Notice for all HeartWare Ventricular Assist System batteries due to potential performance issues.
Why it matters: Battery performance issues in the HeartWare Ventricular Assist System could lead to device malfunction, posing serious risks to patients reliant on the system for cardiac support.
Practical implication: Identify and quarantine affected HeartWare batteries; follow manufacturer's instructions for battery management and replacement; ensure patients and healthcare providers are informed.
Published from the Firecrawl agent regulatory extraction pipeline.
Importers of the affected glass containers must guarantee the payment of the anti-dumping duty for a period of six months from the effective date.
Organizations must review and update compliance protocols in response to expanded trade prohibitions and prepare for restrictions on Iranian aviation effective immediately.
Review and adjust labeling and compliance processes for affected combination products as per the new regulations.
Stakeholders should prepare for discussions regarding veterinary medicinal product reviews, specifically focusing on maximum residue limits and ensure all interests are declared by participants.
